Plum SEC
  • Korean Market
  • Privacy Policy

Korean Market

  • Reset (View All)

  • ★★★★★
  • ★★★★
  • ★★★
  • ★★
  • ★

  • ★

  • ★
  • ★★
  • ★★★
  • ★★★★
  • ★★★★★
All Disclosures
EXCH
Aimed Bio
★

Aimed Bio Files FDA Phase 1 Clinical Trial Application for BI 4060107 in Solid Tumors... Neutral Impact on Shareholder Value

  05/27/2026, 09:24 AM
PERI
Aimed Bio
★★

AimedBio: Tech Transfer Revenue Surges, but R&D Costs Widen Loss

  05/15/2026, 02:55 PM
PERI
Aimed Bio
★★

AimedBio Q1 2026: Tech Transfer Revenue Surges, Operating Loss Persists

  05/15/2026, 07:30 AM
EXCH
Aimed Bio
★★

Receipt of R&D Milestone Payment from ODS025 Technology Transfer Agreement (Min. ~4.73B KRW)

  05/06/2026, 06:11 PM
한국어 | English | 中文 | 日本語
Plum SEC © 2026.05.25
The information provided on this site is for reference only and we do not guarantee its accuracy or completeness. Users are solely responsible for any investment decisions made based on this information.